CL2013002486A1 - Compuestos derivados de 6,7-dihidropirazolo [1,5-a]pirazin-4-il-amina, inhibidores de beta - secretasa (bace); composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, senilidad, demencia, sindrome de down, entre otras. - Google Patents

Compuestos derivados de 6,7-dihidropirazolo [1,5-a]pirazin-4-il-amina, inhibidores de beta - secretasa (bace); composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, senilidad, demencia, sindrome de down, entre otras.

Info

Publication number
CL2013002486A1
CL2013002486A1 CL2013002486A CL2013002486A CL2013002486A1 CL 2013002486 A1 CL2013002486 A1 CL 2013002486A1 CL 2013002486 A CL2013002486 A CL 2013002486A CL 2013002486 A CL2013002486 A CL 2013002486A CL 2013002486 A1 CL2013002486 A1 CL 2013002486A1
Authority
CL
Chile
Prior art keywords
dementia
beta
bace
disease
down syndrome
Prior art date
Application number
CL2013002486A
Other languages
English (en)
Inventor
Henricus Jacobus Maria Gijsen
Gool Michiel Luc Maria Van
Ramiro Juan Antonio Vega
Francisca Delgado-Jiménez
Andrés Avelino Trabanco-Suárez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2013002486A1 publication Critical patent/CL2013002486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4-IL-AMINA COMO INHIBIDORES DE BETA-SECRETASA, CONOCIDA TAMBIÉN COMO LA ENZIMA QUE ESCINDE LA PROTEÍNA PRECURSORA DE AMILOIDE POR EL SITIO BETA, BACE, BACE1, ASP2 O MEMAPSINA 2. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS, Y AL USO DE TALES COMPUESTOS PARA PREVENIR Y TRATAR TRASTORNOS EN LOS QUE PARTICIPA LA BETA-SECRETASA, TALES COMO LA ENFERMEDAD DE ALZHEIMER (EA), EL DETERIORO COGNITIVO LEVE, SENILIDAD, DEMENCIA, DEMENCIA CON CUERPOS DE LEWY, SÍNDROME DE DOWN, DEMENCIA ASOCIADA CON EL ACCIDENTE CEREBROVASCULAR, DEMENCIA ASOCIADA CON LA ENFERMEDAD DE PARKINSON O DEMENCIA ASOCIADA CON BETA-AMILOIDES. LA FÓRMULA GENERAL 1 DE LOS COMPUESTOS DE LA INVENCIÓN CORRESPONDEN A: DONDE R1 , R 2 , R 3 , X 1 , X2 , X3 , X4 , L Y AR SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA.
CL2013002486A 2011-03-01 2013-08-28 Compuestos derivados de 6,7-dihidropirazolo [1,5-a]pirazin-4-il-amina, inhibidores de beta - secretasa (bace); composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, senilidad, demencia, sindrome de down, entre otras. CL2013002486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11156463 2011-03-01

Publications (1)

Publication Number Publication Date
CL2013002486A1 true CL2013002486A1 (es) 2014-02-21

Family

ID=45808845

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002486A CL2013002486A1 (es) 2011-03-01 2013-08-28 Compuestos derivados de 6,7-dihidropirazolo [1,5-a]pirazin-4-il-amina, inhibidores de beta - secretasa (bace); composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, senilidad, demencia, sindrome de down, entre otras.

Country Status (27)

Country Link
US (1) US9346811B2 (es)
EP (1) EP2681219B1 (es)
JP (1) JP5853033B2 (es)
KR (1) KR102012671B1 (es)
CN (1) CN103415519B (es)
AU (1) AU2012222394B2 (es)
BR (1) BR112013022039A2 (es)
CA (1) CA2824360C (es)
CL (1) CL2013002486A1 (es)
CO (1) CO6751282A2 (es)
CY (1) CY1117663T1 (es)
DK (1) DK2681219T3 (es)
EA (1) EA022649B1 (es)
ES (1) ES2558779T3 (es)
HK (1) HK1188784A1 (es)
HR (1) HRP20160030T1 (es)
HU (1) HUE026338T2 (es)
IL (1) IL228158A (es)
MX (1) MX338333B (es)
MY (1) MY161407A (es)
PL (1) PL2681219T3 (es)
PT (1) PT2681219E (es)
SG (1) SG192963A1 (es)
SI (1) SI2681219T1 (es)
UA (1) UA109800C2 (es)
WO (1) WO2012117027A1 (es)
ZA (1) ZA201306545B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
TWI537263B (zh) 2010-06-09 2016-06-11 健生藥品公司 使用作為β－分泌酶抑制劑之５，６－二氫－２Ｈ－［１，４］－３－基－胺衍生物
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
EP2634186A4 (en) 2010-10-29 2014-03-26 Shionogi & Co naphthyridine
AU2011347377B2 (en) 2010-12-22 2016-03-03 Janssen Pharmaceutica Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
HUE026338T2 (en) 2011-03-01 2016-05-30 Janssen Pharmaceutica Nv Beta-secretase (BACE) inhibitors 6,7-dihydro-pyrazolo [1,5-a] pyrazin-4-ylamine derivatives
HRP20211967T1 (hr) 2011-03-01 2022-03-18 NuCana plc Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka
SG193342A1 (en) 2011-03-09 2013-10-30 Janssen Pharmaceutica Nv 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
EP3008066B1 (en) * 2013-06-12 2018-08-15 Janssen Pharmaceutica N.V. 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
CA2911693C (en) * 2013-06-12 2021-08-24 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
EA032662B1 (ru) * 2013-06-12 2019-06-28 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 4-АМИНО-6-ФЕНИЛ-5,6-ДИГИДРОИМИДАЗО[1,5-а]ПИРАЗИН-3(2H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE)
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
WO2023243616A1 (ja) * 2022-06-13 2023-12-21 塩野義製薬株式会社 ジヒドロピリジノン誘導体またはその溶媒和物の結晶

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188389A (en) 1978-11-03 1980-02-12 Ayerst Mckenna & Harrison, Inc. 1,2,3,4-Tetrahydropyrrolo(1,2-A)pyrazines
TW224974B (es) 1991-07-02 1994-06-11 Hoffmann La Roche
US6919340B2 (en) 2002-04-19 2005-07-19 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
KR20050057520A (ko) 2002-09-23 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피라진
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
EP1615931A1 (en) * 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
WO2005108391A1 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Amides as bace inhibitors
WO2006009653A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
TW200624426A (en) 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
WO2006076284A2 (en) 2005-01-14 2006-07-20 Wyeth AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE
US20070005404A1 (en) 2005-06-09 2007-01-04 Drive Diagnostics Ltd. System and method for providing driving insurance
KR20080028881A (ko) 2005-06-14 2008-04-02 쉐링 코포레이션 헤테로사이클릭 아스파르틸 프로테아제 억제제, 이의제조방법 및 용도
WO2007005404A1 (en) 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
GB2443654A (en) 2006-05-30 2008-05-14 Matthew Emmerson Allen System for detecting and testing drivers who show abnormal driving behaviour.
TW200815443A (en) * 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
CN101501040A (zh) * 2006-06-14 2009-08-05 阿斯利康(瑞典)有限公司 氨基-咪唑啉以及它们作为治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物的用途
US20080051420A1 (en) * 2006-06-14 2008-02-28 Astrazeneca Ab New Compounds 317
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
JP2011502122A (ja) 2007-10-30 2011-01-20 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒスタミンｈ３関連障害の治療のために有用なヒスタミンｈ３−レセプターの調節因子としてのビフェニル誘導体
AU2009209295A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica Nv 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE)
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2011002409A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
WO2011058763A1 (ja) 2009-11-13 2011-05-19 塩野義製薬株式会社 アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US20120258961A1 (en) 2009-12-24 2012-10-11 Shionogi & Co., Ltd. 4-amino-1,3-thiazine or oxazine derivative
ES2445536T3 (es) 2009-12-31 2014-03-03 Novartis Ag Derivados de la pirazina y su uso en el tratamiento de trastornos neurológicos
TWI537263B (zh) * 2010-06-09 2016-06-11 健生藥品公司 使用作為β－分泌酶抑制劑之５，６－二氫－２Ｈ－［１，４］－３－基－胺衍生物
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
AU2011347377B2 (en) 2010-12-22 2016-03-03 Janssen Pharmaceutica Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
US9242943B2 (en) 2011-01-18 2016-01-26 Siena Biotech S.P.A. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
HUE026338T2 (en) 2011-03-01 2016-05-30 Janssen Pharmaceutica Nv Beta-secretase (BACE) inhibitors 6,7-dihydro-pyrazolo [1,5-a] pyrazin-4-ylamine derivatives
SG193342A1 (en) 2011-03-09 2013-10-30 Janssen Pharmaceutica Nv 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
EA201490774A1 (ru) 2011-10-13 2014-08-29 Новартис Аг Новые производные оксазина и их применение при лечении заболевания

Also Published As

Publication number Publication date
KR20140010052A (ko) 2014-01-23
IL228158A (en) 2016-07-31
NZ614551A (en) 2014-06-27
HK1188784A1 (zh) 2014-05-16
MX338333B (es) 2016-04-11
CN103415519B (zh) 2016-03-02
ES2558779T3 (es) 2016-02-08
JP5853033B2 (ja) 2016-02-09
AU2012222394A1 (en) 2013-07-25
EA201391251A1 (ru) 2014-01-30
US20140005200A1 (en) 2014-01-02
CA2824360C (en) 2020-01-14
HUE026338T2 (en) 2016-05-30
PT2681219E (pt) 2016-02-10
MX2013010040A (es) 2013-11-04
CA2824360A1 (en) 2012-09-07
CY1117663T1 (el) 2017-05-17
MY161407A (en) 2017-04-14
PL2681219T3 (pl) 2016-03-31
HRP20160030T1 (hr) 2016-02-12
IL228158A0 (en) 2013-11-25
EA022649B1 (ru) 2016-02-29
BR112013022039A2 (pt) 2016-11-29
AU2012222394B2 (en) 2016-06-16
UA109800C2 (xx) 2015-10-12
CN103415519A (zh) 2013-11-27
EP2681219B1 (en) 2015-10-28
CO6751282A2 (es) 2013-09-16
WO2012117027A1 (en) 2012-09-07
KR102012671B1 (ko) 2019-08-21
ZA201306545B (en) 2015-03-25
SI2681219T1 (sl) 2016-02-29
US9346811B2 (en) 2016-05-24
EP2681219A1 (en) 2014-01-08
SG192963A1 (en) 2013-09-30
JP2014506907A (ja) 2014-03-20
DK2681219T3 (en) 2016-01-18

Similar Documents

Publication Publication Date Title
CL2013002486A1 (es) Compuestos derivados de 6,7-dihidropirazolo [1,5-a]pirazin-4-il-amina, inhibidores de beta - secretasa (bace); composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, senilidad, demencia, sindrome de down, entre otras.
CL2013002511A1 (es) Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina, inhibidores de (bace); composicion farmaceutica que los comprende; proceso de preparacion; util para el tratamiento o prevencion de la enfermedad de alzheimer, demencia, sindrome de down y otras demencias asociadas con beta-amiloides.
CO6660450A2 (es) Derivados de 4,7-dihidro-pirazol[1,5-a]pirazin-6-ilamina útiles como inhibidoresde beta-secretasa (bace)
CO6602112A2 (es) Derivados de 5.6- dhidro-2h -[1.4]oxazin-3-il amina utiles como inhibidores de la betasecretasa(bace)
CO6721049A2 (es) Derivados de 5,6-dihiro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de beta secretasa (bace)
CO6541656A2 (es) 2-amino-5.5- difluor-5.6-dihidro-4h-oxazinas como inhibidores de bace1 y/o bace 2
GT201200016A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EA201291366A1 (ru) Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
PA8779901A1 (es) Compuestos amino-heterocíclicos
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
CL2009000954A1 (es) Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras.
CL2008001921A1 (es) Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras.
BR112012033291A2 (pt) derivados de 3-amino-5,6-di-hidro-1h-piranzin-2-ona úteis para o tratamento de doença de alzheimer e outras formas de demência
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
MX357383B (es) Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
MX2017008083A (es) Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
CL2011002907A1 (es) Compuestos derivados de nitrilo; sus composiciones farmacéuticas y su uso para el tratamiento de enfermedades hiperproliferativas.
CL2008002088A1 (es) Compuestos derivados de fenilo sustituido, moduladores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos cognitivos tales como demencia, alzheimer, entre otros.
UY32875A (es) Derivados de benzodiazepinas para tratar infección de hepatitis c.
CL2012001500A1 (es) Procedimiento de preparacion de hidrocloruro de 4-{3-[cis-hexahidrociclopenta [c]pirrol-2(1h)-il]propoxi}benzamida; formas cristalinas de la base libre y del hidrocloruro; compuestos intermediarios; composiciones farmaceuticas que los contienen; y su uso en el tratamiento de trastornos cognitivos y enfermedades neurodegenerativas.